QUIA Stock Overview
QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders.
QuiaPEG Pharmaceuticals Holding AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr0.12|
|52 Week High||kr0.63|
|52 Week Low||kr0.052|
|1 Month Change||74.63%|
|3 Month Change||17.00%|
|1 Year Change||-77.59%|
|3 Year Change||n/a|
|5 Year Change||-94.03%|
|Change since IPO||-97.29%|
Recent News & Updates
|QUIA||SE Biotechs||SE Market|
Return vs Industry: QUIA underperformed the Swedish Biotechs industry which returned -16% over the past year.
Return vs Market: QUIA underperformed the Swedish Market which returned -21.3% over the past year.
|QUIA Average Weekly Movement||31.2%|
|Biotechs Industry Average Movement||8.2%|
|Market Average Movement||7.3%|
|10% most volatile stocks in SE Market||12.4%|
|10% least volatile stocks in SE Market||4.5%|
Stable Share Price: QUIA is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 31% a week.
Volatility Over Time: QUIA's weekly volatility has increased from 19% to 31% over the past year.
About the Company
QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products.
QuiaPEG Pharmaceuticals Holding AB (publ) Fundamentals Summary
|QUIA fundamental statistics|
Is QUIA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|QUIA income statement (TTM)|
|Cost of Revenue||kr3.68m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.094|
|Net Profit Margin||-400.69%|
How did QUIA perform over the long term?See historical performance and comparison